drugset / Trial / NCT00336674
Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes
RandomizedParallel-groupTriple-blindPrevention
Summary
In people with type 1 diabetes the beta cells of the pancreas no longer make insulin because the body's immune system has attacked and destroyed the beta cells. It is thought that exposure of the mucous membranes to insulin may cause act like a vaccine effect whereby protective immune cells are stimulated and these then counteract the "bad" immune cells that damage the beta cells. This study aims to determine if intranasal insulin can protect beta cells and stop progression to diabetes in individuals who are at risk.
Timeline
- Start
- 2006-12
- Primary completion
- 2019-11-13
- Completion
- 2019-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Insulin | Protein / enzyme biologic | 440 iu | Intranasal |